Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)Loretta J. Nastoupil, Christopher R. Flowers, Amy Ayers et al.|Blood|2023Cited by 7